Correct usage and dosage of entrectinib/Luo Shengquan

Entrectinib (Entrectinib) is administered orally and must be used strictly in accordance with the doctor's prescription. For adult patients with non-small cell lung cancer, the usual recommended dose is 600 mg once daily until the disease progresses or the patient cannot tolerate the side effects of the drug. When treating a wide range of solid tumors, the adult dose is also 600 mg orally daily. The simplicity of this dosing regimen enables better patient compliance in long-term management.

In pediatric patients, dosage design is more refined. For children 1 to 6 months old, the recommended dose is 250 mg/m² once daily; for children over 6 months old, the dose is calculated based on body surface area (BSA) until the recommended adult dose is reached. For children and adolescents with BSA ≥ 1.5 m², it is recommended to take 600 mg orally daily, which is consistent with adults. This dosage adjustment method based on body surface area not only ensures the safety of the drug in different age groups, but also takes into account the efficacy.

It is recommended to take entrectinib at a fixed time every day to maintain stable blood concentration. Patients need to avoid increasing or decreasing the dose or using it intermittently on their own, otherwise it may lead to a decrease in efficacy or even an increase in the risk of drug resistance. In addition, the medication may be accompanied by adverse reactions such as fatigue, loss of appetite, gastrointestinal discomfort, etc. Most of these conditions can be improved through doctor's adjustment and supportive treatment.

From the overseas guidelines, the recommended usage of entrectinib is consistent with that in China, emphasizing the principle of "continuous treatment", that is, as long as the patient benefits and the side effects are controllable, it should be continued to be taken. It is worth noting that drug interactions may affect its efficacy, and patients should avoid using strong CYP3A inhibitors or inducers while taking it, as these will change the metabolism levels of entrectinib in the body.

Reference materials:https://www.roche.com/products/rozlytrek